X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (89) 89
hematology (68) 68
female (62) 62
male (61) 61
middle aged (60) 60
index medicus (54) 54
aged (52) 52
adult (43) 43
life sciences (29) 29
treatment outcome (25) 25
oncology (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (21) 21
cyclophosphamide (21) 21
cancer (20) 20
aged, 80 and over (19) 19
prognosis (19) 19
leukemia, lymphocytic, chronic, b-cell - drug therapy (18) 18
rituximab (17) 17
chemotherapy (16) 16
retrospective studies (16) 16
therapy (14) 14
antineoplastic combined chemotherapy protocols - adverse effects (13) 13
disease-free survival (13) 13
lymphomas (13) 13
cll (12) 12
human health and pathology (12) 12
survival (12) 12
antineoplastic agents - therapeutic use (11) 11
care and treatment (11) 11
chronic lymphocytic leukemia (11) 11
lymphoma (11) 11
non-hodgkins-lymphoma (11) 11
survival analysis (11) 11
survival rate (11) 11
abridged index medicus (10) 10
cyclophosphamide - administration & dosage (10) 10
fludarabine (10) 10
hemic and lymphatic diseases (10) 10
leukemia (10) 10
research (10) 10
time factors (10) 10
diagnosis (9) 9
follow-up studies (9) 9
vidarabine - analogs & derivatives (9) 9
antibodies, monoclonal, murine-derived - administration & dosage (8) 8
b-cell lymphoma (8) 8
chronic lymphocytic-leukemia (8) 8
cytarabine - administration & dosage (8) 8
france (8) 8
leukemia, lymphocytic, chronic, b-cell - pathology (8) 8
prospective studies (8) 8
recurrence (8) 8
remission induction (8) 8
risk factors (8) 8
[sdv]life sciences [q-bio] (7) 7
adolescent (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
apoptosis (7) 7
expression (7) 7
immunology (7) 7
minimal residual disease (7) 7
transplantation (7) 7
young adult (7) 7
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (6) 6
antibodies, monoclonal, murine-derived - therapeutic use (6) 6
antineoplastic agents - administration & dosage (6) 6
cells (6) 6
cyclophosphamide - therapeutic use (6) 6
hematology, oncology and palliative medicine (6) 6
leukemia, lymphocytic, chronic, b-cell - genetics (6) 6
leukemia, lymphocytic, chronic, b-cell - mortality (6) 6
neoplasm staging (6) 6
oncology, experimental (6) 6
open-label (6) 6
patients (6) 6
salvage therapy (6) 6
vidarabine - administration & dosage (6) 6
[ sdv.mhep.hem ] life sciences [q-bio]/human health and pathology/hematology (5) 5
analysis (5) 5
chlorambucil (5) 5
cyclophosphamide - adverse effects (5) 5
disease progression (5) 5
france - epidemiology (5) 5
gastroenterology & hepatology (5) 5
gene (5) 5
immunotherapy (5) 5
kaplan-meier estimate (5) 5
lymphoma, b-cell - pathology (5) 5
lymphoma, follicular - drug therapy (5) 5
medicine, general & internal (5) 5
stem cells (5) 5
studies (5) 5
trial (5) 5
[ sdv.imm ] life sciences [q-bio]/immunology (4) 4
acute disease (4) 4
alemtuzumab (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
antineoplastic agents - adverse effects (4) 4
b-lymphocytes - pathology (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2011, Volume 377, Issue 9759, pp. 42 - 51
Journal Article
JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 21, pp. 2099 - 2110
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 6, pp. 525 - 533
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 11/2017, Volume 43, Issue 11, pp. 1613 - 1625
Microbiological diagnosis (MD) of infections remains insufficient. The resulting empirical antimicrobial therapy leads to multidrug resistance and... 
Pediatrics | Pain Medicine | Emergency Medicine | Pneumology/Respiratory System | Medicine & Public Health | Intensive / Critical Care Medicine | Sepsis | Anesthesiology | Aetiological source | Bacteremia | PCR | DIAGNOSIS | COST-EFFECTIVENESS | GUIDELINES | NEUTROPENIC PATIENTS | DE-ESCALATION | DISEASES SOCIETY | SEPTIC SHOCK | BLOOD-STREAM INFECTIONS | EPIDEMIOLOGY | SEVERE SEPSIS | CRITICAL CARE MEDICINE | Endocarditis - blood | Febrile Neutropenia - mortality | Humans | Middle Aged | Sepsis - diagnosis | Intensive Care Units - statistics & numerical data | Male | Molecular Diagnostic Techniques - economics | Time-to-Treatment - economics | Anti-Bacterial Agents - therapeutic use | Endocarditis - diagnosis | Time Factors | Endocarditis - mortality | Female | Retrospective Studies | Febrile Neutropenia - diagnosis | Hospital Mortality | Risk Factors | Sepsis - mortality | Cross-Over Studies | Febrile Neutropenia - blood | Quality Improvement | Cost-Benefit Analysis | Intention to Treat Analysis | Aged | Sepsis - blood | Diagnosis | Health aspects | Endocarditis | Health care | Intervention | Pathogens | Multidrug resistance | Infections | Clustering | Patients | Empirical analysis | Blood | Confidence intervals | Randomization | Multilevel | Clusters | Diagnostic systems | Cost analysis | Neutropenia | Life Sciences | Microbiology and Parasitology | Mycology | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2010, Volume 363, Issue 26, pp. 2511 - 2521
In this study, adding pegylated interferon alfa-2a to imatinib therapy for chronic myeloid leukemia resulted in a greater reduction in the number of cells... 
CHRONIC MYELOGENOUS LEUKEMIA | CHROMOSOME | MEDICINE, GENERAL & INTERNAL | INTERFERON | CML | ABL TYROSINE KINASE | HEMATOPOIETIC STEM-CELLS | FOLLOW-UP | PATIENTS RECEIVING IMATINIB | QUIESCENT | CYTARABINE | Piperazines - administration & dosage | Humans | Leukemia, Myeloid, Chronic-Phase - pathology | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Polyethylene Glycols - adverse effects | Male | Proto-Oncogene Proteins c-abl - analysis | Cytarabine - adverse effects | Recombinant Proteins | RNA, Neoplasm - analysis | Adult | Female | Transcription, Genetic | Neutropenia - chemically induced | Proto-Oncogene Proteins c-abl - genetics | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - drug therapy | Anemia - chemically induced | Treatment Outcome | Thrombocytopenia - chemically induced | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Fusion Proteins, bcr-abl - genetics | Fusion Proteins, bcr-abl - analysis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Stem Cells - drug effects | Interferon-alpha - adverse effects | Benzamides | Drug therapy | Chronic myeloid leukemia | Medical research | Kinases | Leukemia | Manuscripts
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2018, Volume 183, Issue 5, pp. 701 - 701
Journal Article
Blood, ISSN 0006-4971, 01/2013, Volume 121, Issue 1, pp. 48 - 53
Journal Article
Journal Article